Cleveland, OHNCT06904482Now EnrollingIRB Ready

aGVHD Clinical Trial in Cleveland, OH

Access cutting-edge agvhd treatment through this clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.

Sponsored by Case Comprehensive Cancer Center

Quick Self-Assessment

See if you qualify for this Cleveland location

Preparing your pre-screening questions…

Expert Care in Cleveland

Access agvhd specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related agvhd treatment provided free

Apply for This Cleveland Location

Check if you qualify for this agvhd clinical trial in Cleveland, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cleveland

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cleveland site if eligible
  4. 4Begin participation

About This aGVHD Study in Cleveland

The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.

Sponsor: Case Comprehensive Cancer Center

Who Can Participate

Inclusion Criteria

Participants with the following hematologic malignancies:
Acute myelogenous leukemia (AML): High-risk AML including:
Antecedent hematological disease (e.g., myelodysplasia (MDS))
Treatment-related
Complete Remission (CR1) with poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
Participants must be in CR1, CR2, CR3 or CRi
Acute lymphoblastic leukemia (ALL)
High-risk CR1 including:
Poor-risk cytogenetics (e.g., t(9;22)or 11q23 rearrangements)
Presence of minimal disease by flow cytometry or PCR or Clonoseq after 2 or more cycles of chemotherapy
No CR within 4 weeks of initial treatment
Participants in CR2 or beyond
Participants must be in CR1, CR2, CR3, or CRi
Myelodysplastic syndromes (MDS), Intermediate, High or Very High Risk by the revised international prognostic scoring system (IPSS-R) or treatment related MDS
High-risk lymphoma
Age \> 18 years
Participants without a suitable HLA-matched related or unrelated donor CASE9Z24 Page 17 Version dated 12.16.2025
Participants with the following suitable grafts:
A 4-8/8 HLA high resolution matched cord blood unit with a cell dose of 1.0x105 CD34 cells/kg.
A haplo-identical donor with a goal cell dose of \> 4.0x106 CD34cells/kg (minimum 2 x106 CD34 cells/kg)
Concurrent Therapy for Extramedullary Leukemia or CNS Lymphoma: Concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated. Such treatment may continue until the planned course is completed. Participants must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement. Maintenance therapy after transplant is allowed.
Participants must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Participants with inadequate Organ Function as defined by:
Creatinine clearance \< 40ml/min (Cockcroft-Gault)
Bilirubin \> 2X institutional upper limit of normal unless Gilbert syndrome
AST (SGOT) \> 3X institutional upper limit of normal
ALT (SGPT) \> 3X institutional upper limit of normal
Pulmonary function: DLCOc \< 60%
Cardiac: left ventricular ejection fraction \< 40%
Participants with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant or breastfeeding women are excluded from this study because chemotherapy involved with RIC have the significant potential for teratogenic or abortifacient effects.
Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Prior autologous stem cell transplant or CAR-T within the preceding 6 months or prior allogeneic transplant.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT06904482) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

aGVHD Treatment Options in Cleveland, OH

If you're searching for agvhd treatment options in Cleveland, OH, this clinical trial (NCT06904482) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced agvhd specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all agvhd clinical trials near you to find additional studies recruiting in your area.

More Huntingtons Disease Trials in Cleveland, OH

See all huntingtons disease clinical trials recruiting in Cleveland — not just this study.

Browse Huntingtons Disease Trials in Cleveland →

Browse More Trials by Condition

Huntingtons Disease TrialsAll Conditions →

Ready to Join in Cleveland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cleveland, OH